The De Grey Mining Limited (ASX: DEG) share price performed exceptionally well on Thursday. Shares in the gold explorer gained momentum throughout the day after the company released infill results to the market.

These results were positively received by investors. In turn, the De Grey share price surged 8.2% to $1.25. However, the ASX-listed mining company wasn’t the only solid performer in the sector today. Other honourable mentions include Fortescue Metals Group Limited (ASX: FMG), Mineral Resources Limited (ASX: MIN), and Evolution Mining Ltd (ASX: EVN) — all trumpeting a gain of more than 4% on Thursday.

With all that being said, let’s take a closer look at De Grey’s latest announcement.

Infill results a positive for the De Grey share price

Investors have been instilled with some additional confidence following De Grey’s published results from today. Importantly, the infill drilling undertaken within the proposed Brolga Stage 1 pit demonstrated consistency in its gold discovery.

Infill drilling is used to give a higher resolution understanding of the discovered mineralisation during a prior drilling program. In short, holes are drilled in between the previously drilled holes to map out exactly where the gold might be located and how much of it.

In De Grey’s latest infill drilling across multiple sections, it was determined that the mineralisation holds consistent throughout much of the scoped area. Unsurprisingly, this result was met with enthusiasm towards the De Grey share price today.

For reference, the proposed Brolga Stage 1 pit comprises 1.29 million ounces at 1.3 grams of gold per tonne. The drilling shared with investors today produced similar numbers, such as:

• 80m at 1.6g/t Au from 36m
• 93m at 2.2g/t Au from 43m
• 127m at 2.0g/t Au from 35m
• 114m at 1.5g/t Au from 126m

Commenting on these results, De Grey general manager exploration, Phil Tornatora said:

The recently announced scoping study of the Mallina Gold Project identified Brolga as an early production source. These new resource infill drilling results successfully demonstrate the continuity of mineralisation within the proposed Brolga Stage 1 pit. Resource infill drilling is reducing project risk associated with early production. The 40m x 40m drill spacing at Brolga is expected to provide a high level of confidence in the early production from Brolga.

Positively, the results give increased confidence in the project’s projected cash flow from early production sources.

Next steps

Following this, De Grey will continue its infill drilling program as part of its pre-feasibility study of the Mallina Gold Project. Specifically, the program is expected to run over a further three months.

Finally, drilling is continuing across the company’s Great Hemi and Regional areas. This includes three aircore and three RC rigs engaged in exploratory activities.

The post De Grey (ASX:DEG) share price leaps 8% as project confidence grows appeared first on The Motley Fool Australia.

More reading

• Why Chalice, De Grey, Estia Health, and Fortescue shares are racing higher
• Why Aurizon, De Grey Mining, Lynas, and Yancoal shares are falling
• De Grey Mining (ASX:DEG) share price sinks 9% after raising $125m
• De Grey (ASX:DEG) share price halted amid $125 million cap raise

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3nceEWZ

Shares in nanotechnology and biotech company Imagion Biosystems Ltd (ASX: IBX) charged higher today to finish 14% in the green. The Imagion Biosystems share price jumped from the open following a company response to a query from the ASX.

The ASX wanted to know why the company’s share price spiked – in almost vertical fashion – over 40% from Friday’s close to finish at 10 cents on Tuesday.

Imagion provided its answers in a detailed response to the ASX that was posted before the open today.

Here are the details.

What’s up with the Imagion Biosystems share price lately?

Backtracking to the final week of October, Imagion released its quarterly report, covering several investment highlights.

The company, which specialises in medical diagnostic imaging technology, advised it had now enrolled multiple patients into a Phase 1 study of its novel imaging agent MagSense.

The study is investigating the safety of MagSense in its intended use, as a non-invasive alternative to detect early-stage HER2 breast cancer.

It also partnered with Global Cancer Technology during the quarter. The pair will develop Global Cancer’s nanoscintillator technology, also potentially indicated in breast cancer albeit on the treatment side.

Imagion is set to receive funding from Global Cancer Technology as the pair combine technologies to search for a breakthrough in the disease segment.

Imagion also funded its first animal studies investigating MagSense as an imaging solution for prostate cancer.

The market appeared to have a delayed reaction to Imagion’s quarterly update. From the close of trading last Friday to Tuesday’s close, the Imagion Biosystems share price roared from 7.1 cents to a 3-month high of 10 cents.

It is this market activity that had the ASX contacting Imagion in search of some answers.

In a standard compliance letter from the ASX’s Melissa Kostopoulous, the company was asked to explain any possible causes for the gain.

“Is IBX aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?”

How did Imagion respond?

The company replied that it was not aware of any such information. It did, however, make mention of the recent quarterly update, and in particular, the additional enrolments into its MagSense Phase 1 trial.

This is important to note because earlier in the year, Imagion had announced it was having difficulty achieving this due to COVID-19.

Even though the first patients had been enrolled, capturing further study participants was proving a challenge for Imagion.

Hence, the announcement it had secured additional patients in the study cohort can be deemed as a net positive for the company. This could have had an impact on its share price, the company said.

Imagion concluded that it is in fact in compliance with all ASX listing rules and requirements.

Imagion Biosystems share price snapshot

The Imagion Biosystems share price has posted a loss of almost 34% since January 1.

Yet, despite this, it has returned 18% to shareholders over the past 12 months. This is ahead of the benchmark S&P/ASX 200 index (ASX: XJO)’s return of around 14.5% in that time.

The post The Imagion Biosystems (ASX:IBX) share price leapt 40% in 2 days this week. What’s happening? appeared first on The Motley Fool Australia.

More reading

• Imagion Biosystems (ASX:IBX) share price soars 13% on quarterly update

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3088qOC

The Dusk Group Ltd (ASX: DSK) share price finished Thursday’s market session lower after the company provided a trading update.

At the closing bell, the specialty retailer’s shares ended at $3.03 a pop, down 3.19%.

Dusk reports fall in sales

Investors drove the Dusk share price lower following the company’s late afternoon market release.

For the 19 weeks ending 7 November, Dusk advised its sales have been impacted as a result of store closures. In particular, New South Wales, Victoria, and the Australian Capital Territory were forced shut by state governments due to COVID-19. This effectively reduced the number of store trading days by around 33% over the period.

Total year-to-date unaudited sales have declined by 22.9% when compared to FY21. It is estimated this metric will be between $10 million and $11 million below the prior corresponding period. In addition, pro-forma earnings before interest, tax, depreciation and, amortisation (EBITDA) will also likely be down around $6 million to $7 million.

Total like-for-like (LFL) sales fell 8.5% when measured against last financial year’s performance. Although, since the reopening of all stores, both states and the territory have delivered positive LFL sales growth.

Another positive is that online sales have continued to surge, achieving a 19% lift versus FY21.

On a year-to-date basis, the company noted that gross margins have increased on the same period in FY21. Elevated freight costs have been offset by a favourable foreign currency position and higher retail prices in June 2021.

The results haven’t impressed investors, judging by the fall in the Dusk share price today. However, Dusk CEO Peter King was optimistic. He commented:

We anticipate that customers will be encouraged to shop in stores in the lead-up to Christmas due to pent-up demand, combined with delays in deliveries for online purchases.

Having opened 6 new stores so far in FY22, we now have 128 stores (including online). With all stores now open and stock levels as planned, we are ready to capitalise upon the key Christmas trading period.

Dusk share price summary

Despite today disappointing results, the Dusk share price has zoomed upwards by 50% in 2021. However, when factoring in the last 12 months, its shares are up by 89%.

Based on today’s price, Dusk commands a market capitalisation of roughly $194.9 million and has approximately 62.3 million shares outstanding.

The post Dusk (ASX:DSK) share price backtracks following sales update appeared first on The Motley Fool Australia.

More reading

• 2 best ASX shares to buy right now: fund manager

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Dusk Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3wyqAVQ

Are you looking to make some additions to your portfolio? If exchange traded funds (ETFs) are of interest to you, then you might want to look at the three listed below.

Here’s what you need to know about them:

BetaShares Global Cybersecurity ETF (ASX: HACK)

The first ASX ETF to look at is the BetaShares Global Cybersecurity ETF. This popular ETF gives investors exposure to the leading companies in the global cybersecurity sector. Due to the growing threat of cyberattacks globally, demand for cybersecurity services has been increasing strongly.

This could see the companies in the fund, which includes the likes of Accenture, Cisco, Cloudflare, Fortinet, Okta, Splunk, Zscaler, Crowdstrike, well-placed for growth over the 2020s.

VanEck Vectors Video Gaming and eSports ETF (ASX: ESPO)

Another ETF for ASX investors to look at is the VanEck Vectors Video Gaming and eSports ETF. This ETF allows investors to buy a piece of the largest companies involved in video game development, hardware, and esports. This includes Activision Blizzard, AMD, Electronic Arts, Nintendo, Nvidia, Roblox, and Take-Two.

VanEck highlights that these companies are well-placed to benefit from the increasing popularity of video games and eSports.

Vanguard MSCI Index International Shares ETF (ASX: VGS)

A final ETF to look at is the Vanguard MSCI Index International Shares ETF. This ETF provides investors with exposure to a massive 1,504 of the world’s largest listed companies from major developed countries. This makes the ETF one of the most diverse options available to investors.

Among the high quality companies you’ll be owning a slice of are Amazon, Apple, Johnson & Johnson, JP Morgan, Nestle, Nvidia, Tesla, and Visa. Vanguard notes that buying this ETF allows investors to take part in the long-term growth potential of international economies.

The post 3 fantastic ETFs for ASX investors in November appeared first on The Motley Fool Australia.

More reading

• Why is the Vanguard MSCI Index International Shares ETF (ASX:VGS) off to such a great start in November?
• Why has the ETFS Semiconductor ETF (ASX:SEMI) leapt 14% in a month?
• 2 compelling ASX shares that could be buys in November 2021
• 3 high quality ETFs getting ASX investors excited
• Why has the BetaShares Global Cybersecurity ETF (ASX:HACK) share price leapt 7% in a month?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended BETA CYBER ETF UNITS and Vanguard MSCI Index International Shares ETF. The Motley Fool Australia owns shares of and has recommended BETA CYBER ETF UNITS. The Motley Fool Australia has recommended VanEck Vectors ETF Trust – VanEck Vectors Video Gaming and eSports ETF and Vanguard MSCI Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/30fbIQh